Hersintuzumab is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ErbB2). By specifically binding to the extracellular domain of HER2, it blocks downstream proliferative signaling pathways (e.g., PI3K/Akt) and mediates antibody-dependent cellular cytotoxicity (ADCC), making it widely used to research therapeutic strategies for HER2-positive malignancies like breast and gastric cancers.
Target:
EGFR
T9901A-1325
* VAT and and shipping costs not included. Errors and price changes excepted
